Garrett Barry

ORCID: 0000-0001-9782-6041
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Anesthesia and Pain Management
  • Nausea and vomiting management
  • Spine and Intervertebral Disc Pathology
  • Breast Cancer Treatment Studies
  • Breast Lesions and Carcinomas
  • Pain Management and Opioid Use
  • CAR-T cell therapy research
  • Cancer Treatment and Pharmacology
  • Anesthesia and Sedative Agents
  • Cardiac, Anesthesia and Surgical Outcomes
  • Lymphoma Diagnosis and Treatment
  • Colorectal Cancer Treatments and Studies
  • Spaceflight effects on biology
  • Health, Medicine and Society
  • Blood transfusion and management
  • Healthcare Systems and Practices
  • Hemoglobinopathies and Related Disorders
  • Genetic factors in colorectal cancer
  • Erythropoietin and Anemia Treatment
  • Gastric Cancer Management and Outcomes
  • Airway Management and Intubation Techniques
  • Lung Cancer Treatments and Mutations
  • Advanced biosensing and bioanalysis techniques
  • Cutaneous lymphoproliferative disorders research
  • Gold and Silver Nanoparticles Synthesis and Applications

Dalhousie University
2020-2024

Queen Elizabeth II Health Sciences Centre
2023

Nova Scotia Health Authority
2020-2022

Izaak Walton Killam Health Centre
2020-2022

University of British Columbia
2014-2016

BC Cancer Agency
2014-2015

Vancouver Coastal Health
2014

Vancouver Coastal Health Research Institute
2014

University of Victoria
2013

Pathophysiology, Diagnosis and Treatment of Bone Diseases
2010

To evaluate the prognostic impact of cell-of-origin (COO) subgroups, assigned using recently described gene expression-based Lymph2Cx assay in comparison with International Prognostic Index (IPI) score and MYC/BCL2 coexpression status (dual expressers).Reproducibility COO assignment was tested employing repeated sampling within tumor biopsies changes reagent lots. The then applied to pretreatment formalin-fixed paraffin-embedded tissue (FFPET) from 344 patients de novo diffuse large B-cell...

10.1200/jco.2014.60.2383 article EN Journal of Clinical Oncology 2015-08-04

NanoString's Prosigna™ Breast Cancer Prognostic Gene Signature Assay is based on the PAM50 gene expression signature. The test outputs a risk of recurrence (ROR) score, category, and intrinsic subtype (Luminal A/B, HER2-enriched, Basal-like). studies described here were designed to validate analytical performance nCounter Analysis System across multiple laboratories.Analytical precision was measured by testing five breast tumor RNA samples 3 sites. Reproducibility replicate tissue sections...

10.1186/1471-2407-14-177 article EN cc-by BMC Cancer 2014-03-13

BackgroundRebound pain is a common, yet under-recognised acute increase in severity after peripheral nerve block (PNB) has receded, typically manifesting within 24 h the was performed. This retrospective cohort study investigated incidence and factors associated with rebound patients who received PNB for ambulatory surgery.MethodsAmbulatory surgery preoperative between March 2017 February 2019 were included. Rebound defined as transition from well-controlled (numerical rating scale [NRS] ≤3)...

10.1016/j.bja.2020.10.035 article EN cc-by-nc-nd British Journal of Anaesthesia 2020-12-31

Surface enhanced Raman scattering (SERS) mapping of biomarkers has shown great promise in determining the distribution proteins interest cells and tissues. Metallic nanoparticle (NP) probes are generally used such mapping. Since SERS intensities from NPs dependent on size, shape, interparticle distance/distribution, it is unclear if this method can provide reliable biomarker quantification. To address problem, we investigated a statistical approach to quantification probe clusters. The...

10.1021/jp404250q article EN The Journal of Physical Chemistry C 2013-07-23

// Garrett S. Barry 1 , Maggie C. Cheang 2 Hector Li Chang Hagen F. Kennecke 3 Department of Pathology and Laboratory Medicine, Faculty University British Columbia, Vancouver, BC V6T 2B5, Canada The Institute Cancer Research, Sutton, London, Surrey SM2 5NG, United Kingdom Medical Oncology, Agency, V5Z 4E6, Correspondence to: Kennecke, e-mail: hkennecke@bccancer.bc.ca Keywords: mCRC, nanostring, ERBB2, HER2, EGFR inhibitor resistance Received: October 19, 2015 Accepted: January 29, 2016...

10.18632/oncotarget.8006 article EN Oncotarget 2016-03-09

The COVID-19 pandemic has increased physician burnout beyond high baseline levels. We aimed to determine whether pandemic-related factors contribute known organizational factors. This was a cross-sectional survey of Canadian physicians using convenience sample. Eligible participants included any currently holding license practice in Canada. Responses were gathered from May 13 12 June 2020. Risk measured the newly developed Pandemic Experiences and Perceptions Scale (PEPS) subscales, contact...

10.1080/13548506.2021.1990366 article EN Psychology Health & Medicine 2021-10-14

With crewed deep space exploration on the horizon, preparation for potential astronaut health crises in missions has become vital. Administration of anaesthesia and analgesia presents many challenges owing to constraints specific (physiologic ergonomic associated with microgravity) nonspecific factors (isolation lack supplies). Regional can be safest option; however, we hypothesised that ergonomics microgravity would compromise ease accuracy nerve blocks.

10.1016/j.bja.2024.07.034 article EN cc-by-nc-nd British Journal of Anaesthesia 2024-09-25

646 Background: Epidermal Growth Factor Receptor Inhibitors (EGFRi) are effective agents in the treatment of mCRC but up to one third KRAS wt tumors do not respond. The primary objective was identify a gene expression signature associated with resistance panitumumab (Pmab) monotherapy and genomic markers resistance. Methods: Patients previously treated codon 12/13 were administered Pmab 6mg/kg IV q2weeks prospective phase II study. endpoint tumor response by RECIST patients progressive...

10.1200/jco.2015.33.3_suppl.646 article EN Journal of Clinical Oncology 2015-01-20

( Can J Anesth / . 2020;67:1704–1709) Acute pain after cesarean delivery (CD) is a predictor of important short-term and long-term outcomes including postpartum depression. Intrathecal opioids are often provided as post-CD analgesia following CD using neuraxial analgesia. However, when spinal anesthesia or intrathecal morphine not good options, truncal blocks local anesthetic wound infiltration (WI) possible alternatives. Common used in this context include the transversus abdominis plane...

10.1097/01.aoa.0000766184.46285.ba article EN Obstetric Anesthesia Digest 2021-08-25
Coming Soon ...